Shernan Holtan, Chief of Blood and Marrow Transplantation and Professor of Medicine at Roswell Park Comprehensive Cancer Center, shared a post on LinkedIn:
“Conflict of research interest: I prescribe sirolimus and also feel myself rapidly aging, so naturally I’ve always wondered if sirolimus helped slow the clock when used in allogeneic HCT. Hats off to Najla El Jurdi and Matt Yousefzadeh for digging into this question!
In this unique pilot analysis, standard sirolimus dosing didn’t meaningfully lower senescence markers compared with cyclosporine. Maybe the senotherapeutic window is narrower than how we use it in BMT, and we still need to look for better ways to address age acceleration after cancer therapy.”
Title: Sirolimus use in allogeneic hematopoietic cell transplant recipients: assessing its senotherapeutic role in a high risk population
Authors: Najla El Jurdi, Heba ElHusseini, Qing Cao, Thomas Klinger, Ella Shapiro, Melike Cömert, Mark Juckett, Shernan Holtan, Matthew Yousefzadeh
Read the full article in Frontiers.
More from Shernan Holtan on OncoDaoly.